Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Brooks Dies

Andrew Brooks, a professor at Rutgers University who was a key figure in the development of saliva-based tests for SARS-CoV-2, has died, People reports. He was 51.

In his role as COO and director of technology development at RUCDR Infinite Biologics, Brooks led the SARS-CoV-2 saliva-based test development effort, Rutgers adds. The test was the first saliva-based test for SARS-CoV-2 to receive an Emergency Use Authorization from the US Food and Drug Administration, in April 2020. Rutgers notes the test was later authorized for home use. "The impact of this approval is significant," Brooks said in a statement at the time of the test's initial authorization. "It means we no longer have to put healthcare professionals at risk for infection by performing nasopharyngeal or oropharyngeal collections."

According to Rutgers, Brooks died unexpectedly last Saturday. In a tweet, New Jersey Governor Phil Murphy, a Democrat, writes that he was "deeply saddened" by learning of Brooks' death. "We cannot thank Andy enough for all he did across his career," Murphy adds. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.